β1-Selective adrenoceptor antagonists increase plasma levels of anti-p2β antibodies and decrease cardiac involvement in chronic progressive chagas heart disease

Canadian Journal of Cardiology

Volumn 30, Issue 3, 2014, Pages 332-337

  Vicco, Miguel H ^a,b   Pujato, Nazarena ^a   Bontempi, Iván ^a   Rodeles, Luz ^b   Marcipar, Iván ^a   Bottasso, Oscar A ^c  

^a UNIVERSIDAD NACIONAL DEL LITORAL   (Argentina)

^b Hospital JBIturraspe Santa Fe   (Argentina)

^c UNIVERSIDAD NACIONAL DE ROSARIO   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC BETA-1 RECEPTOR ANTAGONISTS; ADULT; ANIMALS; ANTIBODIES, PROTOZOAN; BIOLOGICAL MARKERS; CHAGAS CARDIOMYOPATHY; CHRONIC DISEASE; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; TRYPANOSOMA CRUZI;

EID: 84894239843     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2013.09.017     Document Type: Article

References (47)

1. Control of Chagas disease: second report of a WHO expert committee. World Health Organ Tech Rep Ser 2002, 905:1-109. World Health Organization.
2. Estimación cuantitativa de la enfermedad de Chagas en las Américas [Quantitative estimate of Chagas disease in the Americas] 2006, Organización Panamericana de la salud, OMS, Montevideo, Uruguay, [in Spanish].
3. Marin-Neto J.A., Rassi A. Update on Chagas heart disease on the first centenary of its discovery. Rev Esp Cardiol 2009, 62:1211-1216.
4. Aparecida da Silva C., Fattori A., Sousa A.L., et al. Determining the C-reactive protein level in patients with different clinical forms of Chagas disease. Rev Esp Cardiol 2010, 63:1096-1099.
5. Almeida Hde O., Teixeira Vde P., dos Reis M.A., Franciscon J.U., Martins E. Nuclear changes in cells parasitized by Trypanosoma cruzi in chronic Chagas disease patients. Rev Soc Bras Med Trop 1987, 20:147-151.
6. Almeida Hde O., Brandão Mda C., dos Reis M.A., Gobbi H., Teixeira Vde P. Denervation and heart disease in patients with chronic Chagas' disease. Arq Bras Cardiol 1987, 48:43-47.
7. Gironès N., Fresno M. Etiology of Chagas disease myocarditis: autoimmunity, parasite persistence, or both?. Trends Parasitol 2003, 19:19-22.
8. Kalil J., Cunha-Neto E. Autoimmunity in Chagas disease cardiomyopathy: fulfilling the criteria at last?. Parasitol Today 1996, 12:396-399.
9. Leon J.S., Engman D.M. Autoimmunity in Chagas heart disease. Int J Parasitol 2001, 31:555-561.
10. Brener Z., Gazzinelli R.T. Immunological control of Trypanosoma cruzi infection and pathogenesis of Chagas disease. Int Arch Allergy Immunol 1997, 114:103-110.
11. Higuchi M.L., de Morais C.F., Pereira-Barreto A.C., et al. The role of active myocarditis in the development of heart failure in chronic Chagas disease: a study based on endomyocardial biopsies. Clin Cardiol 1987, 10:665-670.
12. Pontes-de-Carvalho L., Santana C.C., Soares M.B., Oliveira G.G., Cunha-Neto E., Ribeiro-dos-Santos R. Experimental chronic Chagas disease myocarditis is an autoimmune disease preventable by induction of immunological tolerance to myocardial antigens. J Autoimmun 2002, 18:131-138.
13. Soares M.B., Pontes-De-Carvalho L., Ribeiro-Dos-Santos R. The pathogenesis of Chagas disease: when autoimmune and parasite-specific immune responses meet. An Acad Bras Cienc 2001, 73:547-559.
14. Coura J.R., Viñas P.A. Chagas disease: a new worldwide challenge. Nature 2010, 465:S6-S7.
15. Coura J.R., Borges-Pereira J. Chagas disease: 100 years after its discovery. A systemic review. Acta Trop 2010, 115:5-13.
16. Cunha-Neto E., Teixeira P.C., Nogueira L.G., Kalil J. Autoimmunity. Adv Parasitol 2011, 76:129-152.
17. Cremaschi G., Fernandez M., Gorelik G., et al. Modulatory effects on myocardial physiology induced by an anti-monoclonal antibody involve recognition of major antigenic epitopes from β-adrenergic and M-muscarinic cholinergic receptors without requiring receptor cross-linking. J Neuroimmunol 2004, 153:99-107.
18. Joensen L., Borda E., Kohout T., Perry S., García G., Sterin-Borda L. Trypanosoma cruzi antigen that interacts with the β1-adrenergic receptor and modifies myocardial contractile activity. Mol Biochem Parasitol 2003, 127:169-177.
19. Ferrari I., Levin M.J., Wallukat G., et al. Molecular mimicry between the immunodominant ribosomal protein P0 of Trypanosoma cruzi and a functional epitope on the human beta 1-adrenergic receptor. J Exp Med 1995, 182:59-65.
20. Labovsky V., Smulski C.R., Gómez K., Levy G., Levin M.J. Anti-beta1-adrenergic receptor autoantibodies in patients with chronic Chagas heart disease. Clin Exp Immunol 2007, 148:440-449.
21. Grippo V., Niborski L.L., Gomez K.A., Levin M.J. Human recombinant antibodies against Trypanosoma cruzi ribosomal P2 β protein. Parasitology 2011, 1-12.
22. Levy G.V., Tasso L.M., Longhi S.A., et al. Antibodies against the Trypanosoma cruzi ribosomal P proteins induce apoptosis in HL-1 cardiac cells. Int J Parasitol 2011, 41:635-644.
23. Matsui S., Fu M.L., Katsuda S., et al. Peptides derived from cardiovascular G-protein-coupled receptors induce morphological cardiomyopathic changes in immunized rabbits. J Mol Cell Cardiol 1997, 29:641-655.
24. López Bergami P., Scaglione J., Levin M.J. Antibodies against the carboxyl-terminal end of the Trypanosoma cruzi ribosomal P proteins are pathogenic. FASEB J 2001, 15:2602-2612.
25. Elies R., Ferrari I., Wallukat G., et al. Structural and functional analysis of the B cell epitopes recognized by anti-receptor autoantibodies in patients with Chagas disease. J Immunol 1996, 157:4203-4211.
26. Bestetti R.B., Otaviano A.P., Cardinalli-Neto A., da Rocha B.F., Theodoropoulos T.A., Cordeiro J.A. Effects of β-blockers on outcome of patients with Chagas cardiomyopathy with chronic heart failure. Int J Cardiol 2011, 151:205-208.
27. Issa V.S., Amaral A.F., Cruz F.D., et al. β-Blocker therapy and mortality of patients with Chagas cardiomyopathy: a subanalysis of the REMADHE prospective trial. Circ Heart Fail 2010, 3:82-88.
28. Quiros F.R., Morillo C.A., Casas J.P., Cubillos L.A., Silva F.A. CHARITY: Chagas cardiomyopathy bisoprolol intervention study: a randomized double-blind placebo force-titration controlled study with bisoprolol in patients with chronic heart failure secondary to Chagas cardiomyopathy [NCT00323973]. Trials 2006, 7:21.
29. Marcipar S, Lagier C. Advances in serological diagnosis of Chagas' disease by using recombinant proteins. In: Rodriguez-Morales A, ed. Current Topics in Tropical Medicine. Available at: . Accessed March 7, 2013. http://www.intechopen.com/books/current-topics-in-tropicalmedicine/advances-in-serological%20.
30. Storino R., Schapachnik E., Barousee J., et al. Clasificación clínica de la miocardiopatía chagásica crónica e historia natural [Clinical classification and natural evolution of chronic Chagas cardiomyopathy]. Bol Acad Nac de Medicina (Bs As) 1985, 63:160. [in Spanish].
31. McMurray J.J., Adamopoulos S., Anker S.D., et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012, 33:1787-1847.
32. Rassi A., Rassi A., Little W.C., et al. Development and validation of a risk score for predicting death in Chagas' heart disease. N Engl J Med 2006, 355:799-808.
33. Barbosa M.M., Nunes M.C. Risk stratification in Chagas disease. Rev Esp Cardiol (Engl Ed) 2012, 65(suppl 2):17-21.
34. Marcipar I.S., Roodveldt C., Corradi G., et al. Use of full-length recombinant calflagin and its c fragment for improvement of diagnosis of Trypanosoma cruzi infection. J Clin Microbiol 2005, 43:5498-5503.
35. Camussone C., Gonzalez V., Belluzo M.S., et al. Comparison of recombinant Trypanosoma cruzi peptide mixtures versus multiepitope chimeric proteins as sensitizing antigens for immunodiagnosis. Clin Vaccine Immunol 2009, 16:899-905.
36. Tijssen, P. Processing of data and reporting of results of enzyme immunoassays. In: Practice and Theory of Enzyme Immunoassays. Laboratory Techniques in Biochemistry and Molecular Biology, Vol. 15. Amsterdam, London, New York, Tokyo: Elsevier, 1985:385-421.
37. Wright P.F., Nilsson E., Van Rooij E.M., Lelenta M., Jeggo M.H. Standardisation and validation of enzyme-linked immunosorbent assay techniques for the detection of antibody in infectious disease diagnosis. Rev Sci Tech 1993, 12:435-450.
38. Aguirre S., Silber A.M., Brito M.E., Ribone M.E., Lagier C.M., Marcipar I.S. Design, construction, and evaluation of a specific chimeric antigen to diagnose chagasic infection. J Clin Microbiol 2006, 44:3768-3774.
39. Acquatella H. Echocardiography in Chagas heart disease. Circulation 2007, 115:1124-1131.
40. Talvani A., Rocha M.O., Ribeiro A.L., Borda E., Sterin-Borda L., Teixeira M.M. Levels of anti-M2 and anti-beta1 autoantibodies do not correlate with the degree of heart dysfunction in Chagas heart disease. Microbes Infect 2006, 8:2459-2464.
41. Brenière S.F., Bosseno M.F., Noireau F., et al. Integrate study of a Bolivian population infected by Trypanosoma cruzi, the agent of Chagas disease. Mem Inst Oswaldo Cruz 2002, 97:289-295.
42. Vicco M.H., Ferini F., Rodeles L., et al. Assessment of cross-reactive host-pathogen antibodies in patients with different stages of chronic Chagas disease. Rev Esp Cardiol 2013, 66:791-796.
43. Bautista-López N.L., Morillo C.A., López-Jaramillo P., et al. Matrix metalloproteinases 2 and 9 as diagnostic markers in the progression to Chagas cardiomyopathy. Am Heart J 2013, 165:558-566.
44. Fabbro D.L., Olivera V., Bizai M.L., et al. Humoral immune response against P2β from Trypanosoma cruzi in persons with chronic Chagas disease: its relationship with treatment against parasites and myocardial damage. Am J Trop Med Hyg 2011, 84:575-580.
45. Marin-Neto J.A., Rassi A., Avezum A., et al. The BENEFIT trial: testing the hypothesis that trypanocidal therapy is beneficial for patients with chronic Chagas heart disease. Mem Inst Oswaldo Cruz 2009, 104(suppl 1):319-324.
46. Szajnbok F.E., Barretto A.C., Mady C., et al. Beneficial effects of enalapril on the diastolic ventricular function in Chagas myocardiopathy. Arq Bras Cardiol 1993, 60:273-278.
47. Botoni F.A., Poole-Wilson P.A., Ribeiro A.L., et al. A randomized trial of carvedilol after renin-angiotensin system inhibition in chronic Chagas cardiomyopathy. Am Heart J 2007, 153. 544.e1-8.